"10.1371_journal.pone.0060408","plos one","2013-04-02T00:00:00Z","Payel Chatterjee; Gaurav S Choudhary; Arishya Sharma; Kamini Singh; Warren D Heston; Jay Ciezki; Eric A Klein; Alexandru Almasan","Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, United States of America; Kent State University, Kent, Ohio, United State of America; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America; Cleveland State University, Cleveland, Ohio, United States of America","Conceived and designed the experiments: PC GSC KS AA. Performed the experiments: PC GSC. Analyzed the data: PC GSC AS KS. Contributed reagents/materials/analysis tools: WDH. Wrote the paper: PC WDH EAK JC AA.","This work was primarily supported by Pfizer RDG. Stock solutions of rucaparib were provided by Pfizer. The authors' colleagues at Clovis Oncology provided suggestions and guidance. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Payel Chatterjee","PC",8,TRUE,4,2,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
